Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Johnson & Johnson’s burgeoning depression treatment Spravato eclipsed $1 billion in revenue in 2024 as the pharma’s neuroscience pipeline comes into view.
Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback